Cadila Healthcare Ltd (Zydus Cadila) and its subsidiary Zydus Pharmaceuticals (USA) Inc on Thursday announced that they have entered into a settlement and license agreement with Somaxon Pharmaceuticals, Inc. and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.
According to a company statement here, Cadila Healthcare and Zydus Pharmaceuticals will now have the right to begin selling a generic version of Silenor 180 days after another party begins selling its generic version in the US. This will be under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon's patents are not infringed, invalid or unenforceable, or earlier under certain circumstances, the release said.